Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Chemosensitization With Paclitaxel, 13-cis Retinoic Acid and Interferon Alpha-2b in Advanced Uterine Cervical Carcinoma

NCT00138151 is registered in ClinicalTrials.gov with University of Medicine and Dentistry of New Jersey as lead sponsor.

NCT NCT00138151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00138151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Chemosensitization With Paclitaxel, 13-cis Retinoic Acid and Interferon Alpha-2b in Advanced Uterine Cervical Carcinoma
Lead sponsor
University of Medicine and Dentistry of New Jersey
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2001
Completion date
November 30, 2010
Enrollment
33 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer